Last May, US President Donald Trump pushed to align drug pricing with the lowest levels among other developed nations — so-called most-favoured-nation (MFN) pricing. However, the pricing policy might have negative consequences.
European patients might have to wait longer for some novel medicines as the US forces drugmakers to offer prices that match those of other high‑income countries, such as Germany or France, according to a new modelling study published in The Lancet.